Adams maintained at outperform by RBC

RBC Capital Markets analyst Ken Trbovich gave Adams Respiratory Therapeutics Inc. an outperform, above average risk rating. The company's first-quarter 2007 earnings per share $0.61 significantly beat the analyst's expectation of $0.45. The upside came from higher sales ($90.1 million) and lower product development expenses ($6.3 million). Trbovich will revisit Adams' decision to postpone Humibid launches when IRI data is released next week. Shares of the Chester, N.J.-based pharmaceutical company were up 28 cents, or 0.67%, at $42.10. (Nasdaq: ARXT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.